LYVE1 and neoplasm: The immunocompetent, syngeneic EMT6 tumor model replicated the progenitor behavior in a xenograft model: nearly 100% of EMT6-recruited Lyve-1+ cells expressed CD11b but only 1–3% co-expressed either Ter-119 or CD3e (Fig 8).